Handelsbanken Fonder
DNLI icon

Handelsbanken Fonder’s Denali Therapeutics DNLI Stock Holding History

Handelsbanken Fonder’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.53M Buy
59,600
+15,800
+36% +$325K ﹤0.01% 936
2026
Q1 		$841K Hold
43,800
– – ﹤0.01% 1110
2025
Q4 		$723K Buy
43,800
+5,500
+14% +$92.8K ﹤0.01% 1182
2025
Q3 		$556K Hold
38,300
– – ﹤0.01% 1226
2025
Q2 		$536K Hold
38,300
– – ﹤0.01% 1215
2025
Q1 		$521K Hold
38,300
– – ﹤0.01% 1226
2024
Q4 		$781K Sell
38,300
-1,200
-3% -$30.7K ﹤0.01% 1093
2024
Q3 		$1.15M Hold
39,500
– – ﹤0.01% 885
2024
Q2 		$917K Buy
39,500
+15,600
+65% +$300K ﹤0.01% 877
2024
Q1 		$490K Hold
23,900
– – ﹤0.01% 1170
2023
Q4 		$513K Buy
23,900
+6,700
+39% +$133K ﹤0.01% 1138
2023
Q3 		$355K Hold
17,200
– – ﹤0.01% 1228
2023
Q2 		$508K Buy
17,200
+3,100
+22% +$87.2K ﹤0.01% 1056
2023
Q1 		$325K Hold
14,100
– – ﹤0.01% 1246
2022
Q4 		$392K Buy
14,100
+700
+5% +$20.8K ﹤0.01% 1092
2022
Q3 		$411K Hold
13,400
– – ﹤0.01% 1073
2022
Q2 		$394K Buy
13,400
+1,600
+14% +$41.9K ﹤0.01% 1165
2022
Q1 		$380K Sell
11,800
-6,200
-34% -$213K ﹤0.01% 1383
2021
Q4 		$803K Hold
18,000
– – ﹤0.01% 1018
2021
Q3 		$908K Hold
18,000
– – ﹤0.01% 953
2021
Q2 		$1.41M Sell
18,000
-200
-1% -$12.4K 0.01% 749
2021
Q1 		$1.04M Buy
18,200
+4,100
+29% +$274K 0.01% 821
2020
Q4 		$1.18M Hold
14,100
– – 0.01% 753
2020
Q3 		$505K Hold
14,100
– – ﹤0.01% 986
2020
Q2 		$341K Buy
+14,100
New +$332K ﹤0.01% 1153

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Handelsbanken Fonder's DNLI Position: Q2 2026 in Review

Handelsbanken Fonder increased its Denali Therapeutics (DNLI) stake by 36% in Q2 2026, buying an estimated $325K and bringing the position to 59,600 shares worth $1.53M. The position accounts for ﹤0.01% of the portfolio, ranked #936.

Handelsbanken Fonder first reported a position in DNLI in Q2 2020 and has held it in 25 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Handelsbanken Fonder held 59,600 shares of Denali Therapeutics worth $1.53M as of Q2 2026.
  • Handelsbanken Fonder bought 15,800 Denali Therapeutics shares in Q2 2026, an estimated $325K.
  • Denali Therapeutics made up ﹤0.01% of Handelsbanken Fonder's portfolio in Q2 2026, its #936 holding.
  • Handelsbanken Fonder first reported a position in Denali Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.